C
Originally published by Capital Businessbusiness
February 18, 2026
3h ago
Kenya receives 21,000 starter doses of injectable HIV prevention drug
Patrick Amoth, director general for health at the ministry, received the consignment on Tuesday evening in Nairobi, the Kenyan capital. He said the first phase of the rollout of Lenacapavir, a long-acting injectable HIV pre-exposure prophylaxis, will begin in early March. Kenya b..
✨ Key Highlights
Kenya's Ministry of Health has received its initial shipment of 21,000 starter doses of Lenacapavir, a twice-yearly injectable drug for HIV prevention, with rollout expected in early March.
- These doses will provide six months of protection per injection for HIV-negative individuals, costing an estimated 7,800 shillings (about 60 U.S. dollars) annually per patient, a significant reduction from 42,000 dollars.
- Director General for Health Patrick Amoth received the consignment, highlighting its role in expanding HIV prevention technologies in the region, with an additional 12,000 continuation doses expected by April.
- Kenya, experiencing over 20,105 new HIV infections in 2025 and with 41 percent of new infections among those under 24 years, will implement a phased rollout targeting 15 high-burden counties first.
Continue Reading
Read the complete article from Capital Business
Advertisement
Related News
Advertisement